Pharma BD Deal Intelligence
Johnson & Johnson to Acquire Firefly Bio for $1 Billion to Expand KRAS-Focused Oncology Pipeline. J&J agreed to acquire Firefly Bio to gain the Firelink…
J&J makes $1B upfront bet in emerging DAC space, netting Firefly Bio. Johnson & Johnson committed $1 billion upfront for Firefly Bio's Firelink…
J&J sets DACs on fire with $1bn acquisition of Firefly Bio. Johnson & Johnson acquired South San Francisco-based Firefly Bio for $1 billion in cash, with the…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Johnson & Johnson agreed to acquire privately held Firefly Bio for $1 billion in cash upfront (plus undisclosed milestones), announced June 8, 2026. The deal brings Firefly's proprietary Firelink degrader-antibody conjugate (DAC) platform, which uses antibodies to deliver targeted protein degraders against hard-to-drug oncology targets including KRAS-driven solid tumors, expanding J&J's oncology pipeline. Expected to close later in 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Firefly Bio, Inc. (this deal) | 2026 | $1.0B | 58 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2026 deals · Johnson & Johnson deals · Oncology deals